Precigen, Inc. I5X.F Stock
Precigen, Inc. Price Chart
Precigen, Inc. I5X.F Financial and Trading Overview
Precigen, Inc. stock price | 1.26 EUR |
Previous Close | 1.43 EUR |
Open | 1.45 EUR |
Bid | 1.46 EUR x 30000 |
Ask | 1.49 EUR x 30000 |
Day's Range | 1.4 - 1.45 EUR |
52 Week Range | 0.78 - 2.86 EUR |
Volume | 700 EUR |
Avg. Volume | 230 EUR |
Market Cap | 378.24M EUR |
Beta (5Y Monthly) | 1.936612 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.36 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 12.5 EUR |
I5X.F Valuation Measures
Enterprise Value | 277.21M EUR |
Trailing P/E | N/A |
Forward P/E | -2.8 |
PEG Ratio (5 yr expected) | -5.93 |
Price/Sales (ttm) | 17.112453 |
Price/Book (mrq) | 2.1505375 |
Enterprise Value/Revenue | 12.542 |
Enterprise Value/EBITDA | -4.178 |
Trading Information
Precigen, Inc. Stock Price History
Beta (5Y Monthly) | 1.936612 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 2.86 EUR |
52 Week Low | 0.78 EUR |
50-Day Moving Average | 1.15 EUR |
200-Day Moving Average | 1.29 EUR |
I5X.F Share Statistics
Avg. Volume (3 month) | 230 EUR |
Avg. Daily Volume (10-Days) | 584 EUR |
Shares Outstanding | 255.48M |
Float | 131.51M |
Short Ratio | N/A |
% Held by Insiders | 10.06% |
% Held by Institutions | 62.42% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | June 30, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 100.21% |
Operating Margin (ttm) | -334.83% |
Gross Margin | -140.60% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -17.49% |
Return on Equity (ttm) | -65.69% |
Income Statement
Revenue (ttm) | 22.1M EUR |
Revenue Per Share (ttm) | 0.1 EUR |
Quarterly Revenue Growth (yoy) | -39.30% |
Gross Profit (ttm) | 20.57M EUR |
EBITDA | -66357000 EUR |
Net Income Avi to Common (ttm) | -72873000 EUR |
Diluted EPS (ttm) | -0.29 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 88.43M EUR |
Total Cash Per Share (mrq) | 0.35 EUR |
Total Debt (mrq) | 7.97M EUR |
Total Debt/Equity (mrq) | 4.79 EUR |
Current Ratio (mrq) | 3.433 |
Book Value Per Share (mrq) | 0.651 |
Cash Flow Statement
Operating Cash Flow (ttm) | -73365000 EUR |
Levered Free Cash Flow (ttm) | 928.88K EUR |
Profile of Precigen, Inc.
Country | Germany |
State | MD |
City | Germantown |
Address | 20374 Seneca Meadows Parkway |
ZIP | 20876 |
Phone | 301 556 9900 |
Website | https://precigen.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 209 |
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments, Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and Lactococcus lactis, a food-grade bacterium. Additionally, it provides RheoSwitch Therapeutic System, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Q&A For Precigen, Inc. Stock
What is a current I5X.F stock price?
Precigen, Inc. I5X.F stock price today per share is 1.26 EUR.
How to purchase Precigen, Inc. stock?
You can buy I5X.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Precigen, Inc.?
The stock symbol or ticker of Precigen, Inc. is I5X.F.
Which industry does the Precigen, Inc. company belong to?
The Precigen, Inc. industry is Biotechnology.
How many shares does Precigen, Inc. have in circulation?
The max supply of Precigen, Inc. shares is 256.51M.
What is Precigen, Inc. Price to Earnings Ratio (PE Ratio)?
Precigen, Inc. PE Ratio is now.
What was Precigen, Inc. earnings per share over the trailing 12 months (TTM)?
Precigen, Inc. EPS is -0.36 EUR over the trailing 12 months.
Which sector does the Precigen, Inc. company belong to?
The Precigen, Inc. sector is Healthcare.